PhenoVista Biosciences and Inventia Life Science Enter Strategic Partnership to Accelerate Preclinical Research with 3D Cell Models
SAN DIEGO, California – PhenoVista Biosciences (PhenoVista), a top provider of custom imaging-based phenotypic assay services, has entered into a partnership with Inventia Life Science (Inventia), a leader in automated generation of complex 3D cell models, to deliver high-content cell-based assay services for drug discovery.
Complex 3D cell culture models, which can more accurately reproduce a physiologically relevant environment in the in vitro setting, are increasingly being implemented in the drug discovery process. Similarly, high-content screening continues to gain traction in the drug discovery services industry, due to its ability to improve physiological relevance and predictive efficacy of drug candidates. With the installation of Inventia’s 3D Cell Culture Platform – RASTRUMTM - at PhenoVista, clients now have access to the companies’ combined expertise in high content phenotypic assays and production of complex 3D cell models in high-throughput. This new joint effort aims to provide next generation complex models using 3D cell cultures for PhenoVista Biosciences’ current oncology and neurobiology focused assay portfolio. Initially spawned through an on-going project with a major Pharma company on two undisclosed targets, the partnership combines PhenoVista’s extensive assay development and imaging experience with Inventia’s automated 3D cell culture platform to help alleviate the major challenges the industry faces to routinely adopt 3D cell models: throughput and reproducibility.
The RASTRUM 3D cell culture platform from Inventia Life Science is quickly gaining global recognition with numerous customers in Australia, Europe and the USA. Its growing international customer base of Pharma, CRO and academic clients are fast adopting the innovative 3D cell model solutions which encompass both healthy and diseased tissue. “The vision for RASTRUM is to revolutionize the way we approach the drug discovery process by accelerating the evolution of drugs from the lab bench to hospital bed.” says Dr. Julio Ribeiro, CEO of Inventia Life Science.
Ray Price, Vice President of Business Development at PhenoVista Biosciences, is enthusiastic about the partnership. “While we already offer access to a broad set of 3D cell-based assay and fluorescence microscopy services, partnering with Inventia to offer access to their automated 3D cell culture platform expands our portfolio in this space, to enable development of even more sophisticated assays.”
About Inventia Life Science
Inventia Life Science is a fast-growing biotech start-up based in Sydney, Australia, that is revolutionizing cancer research, drug discovery and regenerative medicine. The award-winning RASTRUM cell culture platform has already been adopted in leading medical research institutes and biotechnology companies which are creating printed 3D tissue mimics that model real biology. In addition, Inventia is already working with clinical partners to advance regenerative medicine in areas such as bioprinted skin for the repair of burns and wounds.
Inventia Life Science Pty Ltd
About PhenoVista Biosciences
PhenoVista Biosciences is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically driven project design and management approach, PhenoVista has a proven track record of delivering high-quality data from robust and scalable assays. PhenoVista’s key advantage lies in the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems with cutting-edge quantitative imaging to deliver clear, actionable output data. For more information, please visit www.PhenoVista.com. Follow PhenoVista on LinkedIn, Twitter, and Facebook.
Raymond Price, PhD
VP, Business Development
PhenoVista Biosciences, LLC